英夫利西单抗治疗的炎症性肠病患者在SARS-CoV-2大流行奥密克戎波期间出现疫苗逃逸、突破性感染和再感染增加
基于CLARITY炎症性肠病研究,比较英夫利西单抗与维得利珠单抗治疗的炎症性肠病患者接种第三剂mRNA疫苗后的抗SARS-CoV-2抗体应答、突破性感染和再感染。英夫利西单抗组抗体浓度较低、抗体半衰期较短,突破性感染和再感染风险较高,但再感染与抗体浓度无关,提示奥密克戎变异株疫苗逃逸。
要点
- 第三剂mRNA疫苗后,英夫利西单抗组抗S RBD抗体浓度低于维得利珠单抗组。
- 英夫利西单抗组突破性感染风险为维得利珠单抗组的2.23倍,再感染风险为2.10倍。
- 再感染主要发生在奥密克戎波期间,且与初始感染后抗核衣壳抗体浓度相关。
核心结论
- 接种第三剂mRNA疫苗后,英夫利西单抗与减弱的血清学应答及更多SARS-CoV-2突破性感染和再感染相关,且这些感染不能被抗S RBD应答幅度预测,提示奥密克戎变异株的疫苗逃逸。
研究设计与样本
- 基于CLARITY炎症性肠病研究,比较英夫利西单抗治疗的炎症性肠病患者与维得利珠单抗治疗的参考队列,评估第三剂疫苗诱导的抗SARS-CoV-2 spike受体结合域抗体应答、突破性感染、再感染和持续口咽部携带。
主要发现
- 第三剂mRNA疫苗后,两组抗S RBD抗体几何平均浓度均升高,但英夫利西单抗组低于维得利珠单抗组:基础两剂为ChAdOx1 nCoV-19时1856 U/mL(5.2)vs 10 728 U/mL(3.1),p<0.0001;基础两剂为BNT162b2时2164 U/mL(4.1)vs 15 116 U/mL(3.4),p<0.0001。
- 第三剂和第四剂mRNA疫苗后,无论基础疫苗组合如何,两组抗S RBD抗体浓度未见差异。
- 第三剂后,英夫利西单抗组抗S RBD抗体半衰期估计短于维得利珠单抗组:37.0天(95%CI 35.6至38.6)vs 52.0天(95%CI 49.0至55.4),p<0.0001。
- 与维得利珠单抗组相比,英夫利西单抗组更易发生SARS-CoV-2突破性感染(HR 2.23,95%CI 1.46至3.38,p=0.00018)和再感染(HR 2.10,95%CI 1.31至3.35,p=0.0019),但该效应与第三剂疫苗后抗S RBD抗体浓度无关。
- 再感染主要发生在奥密克戎波期间,并由初始感染后SARS-CoV-2抗核衣壳抗体浓度预测;未观察到SARS-CoV-2持续口咽部携带;两组住院和死亡均不常见。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Antitumour necrosis factor (TNF) drugs impair serological responses following SARS-CoV-2 vaccination. We sought to assess if a third dose of a messenger RNA (mRNA)-based vaccine substantially boosted anti-SARS-CoV-2 antibody responses and protective immunity in infliximab-treated patients with IBD. DESIGN: Third dose vaccine induced anti-SARS-CoV-2 spike (anti-S) receptor-binding domain (RBD) antibody responses, breakthrough SARS-CoV-2 infection, reinfection and persistent oropharyngeal carriage in patients with IBD treated with infliximab were compared with a reference cohort treated with vedolizumab from the impaCt of bioLogic therApy on saRs-cov-2 Infection and immuniTY (CLARITY) IBD study. RESULTS: Geometric mean (SD) anti-S RBD antibody concentrations increased in both groups following a third dose of an mRNA-based vaccine. However, concentrations were lower in patients treated with infliximab than vedolizumab, irrespective of whether their first two primary vaccine doses were ChAdOx1 nCoV-19 (1856 U/mL (5.2) vs 10 728 U/mL (3.1), p<0.0001) or BNT162b2 vaccines (2164 U/mL (4.1) vs 15 116 U/mL (3.4), p<0.0001). However, no differences in anti-S RBD antibody concentrations were seen following third and fourth doses of an mRNA-based vaccine, irrespective of the combination of primary vaccinations received. Post-third dose, anti-S RBD antibody half-life estimates were shorter in infliximab-treated than vedolizumab-treated patients (37.0 days (95% CI 35.6 to 38.6) vs 52.0 days (95% CI 49.0 to 55.4), p<0.0001).Compared with vedolizumab-treated, infliximab-treated patients were more likely to experience SARS-CoV-2 breakthrough infection (HR 2.23 (95% CI 1.46 to 3.38), p=0.00018) and reinfection (HR 2.10 (95% CI 1.31 to 3.35), p=0.0019), but this effect was uncoupled from third vaccine dose anti-S RBD antibody concentrations. Reinfection occurred predominantly during the Omicron wave and was predicted by SARS-CoV-2 antinucleocapsid concentrations after the initial infection. We did not observe persistent oropharyngeal carriage of SARS-CoV-2. Hospitalisations and deaths were uncommon in both groups. CONCLUSIONS: Following a third dose of an mRNA-based vaccine, infliximab was associated with attenuated serological responses and more SARS-CoV-2 breakthrough infection and reinfection which were not predicted by the magnitude of anti-S RBD responses, indicative of vaccine escape by the Omicron variant. TRIAL REGISTRATION NUMBER: ISRCTN45176516.
引用
- Kennedy NA, Janjua M, Chanchlani N, et al. Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic. Gut. 2022. PMID: 35902214. doi:10.1136/gutjnl-2022-327570
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。